MapLight Therapeutics, Inc.: shareholders and insiders

MPLTNASDAQHealthcare · Pharmaceutical Preparations

Price

$5.94

November 20, 2026Market cap $315M

What Ploutos Investor adds for MapLight Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors, from their own Form 4 filings.

Reading the newest filings from the SEC. This part fills in on its own in a few seconds.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

4 Holders over 5%1 On a 13DAug 20, 2026 Latest filing
  • Catalyst4, Inc.with 3 more persons
    Share of class49.9%
  • T. Rowe Price Investment Management, Inc.
    Share of class7.40%
  • Forbion Growth Opportunities Fund III Cooperatief U.A.with 1 more personVoting Common Stock, par value $0.0001 per share
    Share of class7.10%
  • Nan Fung Group Holdings Limitedwith 9 more persons
    Share of class5.50%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Catalyst4, Inc.49.9%From the filing of Aug 18, 2026

    Item 4 of the Original Schedule 13D is hereby amended as follows: On August 13, 2026, Catalyst entered into a securities purchase agreement, which is filed as Exhibit 99.4 to this Statement ("Securities Purchase Agreement") with the Issuer, pursuant to which the Catalyst agreed to purchase an aggregate of (i) 4,400,000 shares of the Issuer's voting common stock and (ii) accompanying pre-funded warrants to purchase up to 2,928,686 shares of voting common stock (the "Pre-Funded Warrants"), which is filed as Exhibit 99.5 to this Statement (the "PIPE Offering"). The purchase price per share of voting common stock is $11.38 per share (the "Purchase Price") and the purchase price for the…

    From the filing of Aug 18, 2026
Fell to 5% or less (1)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Novo Holdings A/S13D4.90%Jul 31, 202613D/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter
  • Citadel Advisors (Griffin)
    In the quarter+232%
  • Millennium Mgmt (Englander)
    In the quarter+229%
  • D.E. Shaw
    In the quarter
  • Renaissance Technologies
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 6.26% of its shares outstanding were held short, +5.5% since the report before.

Shares held short
3.32M
6.26%
Since the report before3.15M on Sep 30, 2026
+5.5%
8.3
399.4K
More days to cover thanof 4,578 US-listed companies with enough volume
85%
Report date
Oct 15, 2026
  • Oct 31, 2025: Shares held short 198.9K
  • Nov 14, 2025: Shares held short 407.2K
  • Nov 28, 2025: Shares held short 763.8K
  • Dec 15, 2025: Shares held short 959.0K
  • Dec 31, 2025: Shares held short 1.93M
  • Jan 15, 2026: Shares held short 1.09M
  • Jan 30, 2026: Shares held short 1.27M
  • Feb 13, 2026: Shares held short 1.37M
  • Feb 27, 2026: Shares held short 1.36M
  • Mar 13, 2026: Shares held short 1.36M
  • Mar 31, 2026: Shares held short 1.42M
  • Apr 15, 2026: Shares held short 1.68M
  • Apr 30, 2026: Shares held short 1.74M
  • May 15, 2026: Shares held short 1.36M
  • May 29, 2026: Shares held short 1.56M
  • Jun 15, 2026: Shares held short 1.90M
  • Jun 30, 2026: Shares held short 2.58M
  • Jul 15, 2026: Shares held short 3.59M
  • Jul 31, 2026: Shares held short 3.58M
  • Aug 14, 2026: Shares held short 3.24M
  • Aug 31, 2026: Shares held short 3.43M
  • Sep 15, 2026: Shares held short 3.30M
  • Sep 30, 2026: Shares held short 3.15M
  • Oct 15, 2026: Shares held short 3.32M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading43.0% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 43.0% of the shares in the reported trades were short sales, against 53.7% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
43.0%
The 14 beforeOct 14, 2026 – Nov 2, 2026
53.7%
Change
-10.7 pts
Short sales a dayon average, of 151.8K shares
65.3K
More than atof 3,666 US-listed companies, same days
27%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 77.3%
  • Oct 15, 2026: Short sales 75.2%
  • Oct 16, 2026: Short sales 77.9%
  • Oct 19, 2026: Short sales 76.4%
  • Oct 20, 2026: Short sales 61.7%
  • Oct 21, 2026: Short sales 40.5%
  • Oct 22, 2026: Short sales 39.7%
  • Oct 23, 2026: Short sales 37.6%
  • Oct 26, 2026: Short sales 64.6%
  • Oct 27, 2026: Short sales 37.5%
  • Oct 28, 2026: Short sales 38.7%
  • Oct 29, 2026: Short sales 64.9%
  • Oct 30, 2026: Short sales 35%
  • Nov 2, 2026: Short sales 43.4%
  • Nov 3, 2026: Short sales 37.1%
  • Nov 4, 2026: Short sales 45.4%
  • Nov 5, 2026: Short sales 54.4%
  • Nov 6, 2026: Short sales 43.8%
  • Nov 9, 2026: Short sales 30.3%
  • Nov 10, 2026: Short sales 29.8%
  • Nov 11, 2026: Short sales 43.4%
  • Nov 12, 2026: Short sales 47%
  • Nov 13, 2026: Short sales 48.7%
  • Nov 16, 2026: Short sales 43.1%
  • Nov 17, 2026: Short sales 46.7%
  • Nov 18, 2026: Short sales 47.3%
  • Nov 19, 2026: Short sales 41.4%
  • Nov 20, 2026: Short sales 45.4%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

12 ETFs holding it0.17% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.17%
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.08%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.04%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.02%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.01%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.00%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.00%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.00%

12 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

106 Managers, Q2 2026$941M Value of their positions
  • Q4 2025: Managers 74
  • Q1 2026: Managers 81
  • Q2 2026: Managers 106

Q2 2026: 106 managers held 26.26M shares, worth $941M. During the quarter 37 opened a position, 12 closed one, 21 added and 27 trimmed.

The largest holders, Q2 2026

  • Novo Holdings A/s
    In the quarter
  • Fcpm Iii Services B.v.
    In the quarter
  • T. Rowe Price Investment Management
    In the quarter-0.7%
  • Goldman Sachs Group
    In the quarter-2.3%
  • Price T Rowe Associates
    In the quarter×12.6
  • BlackRock
    In the quarter-23%
  • Nan Fung Group Holdings
    In the quarter
  • 5AM Venture Management
    In the quarter
  • Sanofi
    In the quarter
  • State Street
    In the quarter+151%

From the SEC's Form 13F data sets, Q4 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do MapLight Therapeutics's filings show?

Who buys and sells is one part of MapLight Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MPLT's shareholders

Didn't find what you were looking for?

Ask us
Which well-known managers hold MPLT?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $4.3M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.